Age-Related Macular Degeneration

Jong, P.T.V.M. de

doi:10.1056/nejmra062326

Cited by 772 publications

(616 citation statements)

References 103 publications

Supporting

Mentioning

606

Contrasting

Unclassified

Order By: Relevance

“…AMD is a neurodegenerative disease characterized by progressive loss of photoreceptors in the macula and surrounding retina [2]. Clinical manifestations of the condition begin with abnormities in the retinal pigment epithelium (RPE); formation of lipoproteinaceous deposits, referred to as drusen in Bruch's membrane, beneath the RPE and above the choroid; focal geographic chorioretinal scarring; and loss of photoreceptors in the macula.…”

Section: Introductionmentioning

confidence: 99%

“…Clinical manifestations of the condition begin with abnormities in the retinal pigment epithelium (RPE); formation of lipoproteinaceous deposits, referred to as drusen in Bruch's membrane, beneath the RPE and above the choroid; focal geographic chorioretinal scarring; and loss of photoreceptors in the macula. Advanced AMD involves an increase in the number and size of drusen deposits, choroidal neovascularization (CNV), and geographic atrophy of RPE and photoreceptors [2][3][4].…”

Section: Introductionmentioning

confidence: 99%

“…Possible mechanisms of AMD development include abnormal extracellular matrix, inflammation, altered RPEchoriocapillary behavior, CNV development due to hypoxia-induced biochemical changes, and oxidative stress [2,10]. AMD might also be the result of RPE dysfunction resulting from the overwhelming oxidative stress, which may lead to endoplasmic reticular (ER)-stress and eventually compromised ER-stress response and cell health [2,4,11,12].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Unfolding the therapeutic potential of chemical chaperones for age-related macular degeneration

Sauer

Patel

Chan

et al. 2008

Expert Review of Ophthalmology

View full text Add to dashboard Cite

SUMMARYRecent studies suggest that pathological processes involved in age-related macular degeneration (AMD) might induce endoplasmic reticulum (ER) stress. Growing evidence demonstrates the ability of chemical chaperones to decrease ER stress and ameliorate ER stress-related disease phenotypes, suggesting that the field of chaperone therapy might hold novel treatments for AMD. In this review, we examine the evidence suggesting a role for ER stress in AMD. Furthermore, we discuss the use of chaperone therapy for the treatment of ER stress-associated diseases, including other neurodegenerative diseases and retinopathies. Finally, we examine strategies for identifying potential chaperone compounds and for experimentally demonstrating chaperone activity in in vitro and in vivo models of human disease.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Unfolding the therapeutic potential of chemical chaperones for age-related macular degeneration

Sauer

Patel

Chan

et al. 2008

Expert Review of Ophthalmology

View full text Add to dashboard Cite

show abstract

“…On estime qu'environ 65 % des patients de 80 ans ou plus ont des signes précoces ou avancés de la maladie [1]. Les patients conservent cependant une autonomie ambulatoire puisque seule la macula est le siège de lésions.…”

unclassified

“…Un polymorphisme d'un nucléotide dans les gènes codant pour les facteurs H (CFH) (chromosome 1q31), B (CFB) et C2 du complément est associé à 50 à 70 % des cas de DMLA, quelle qu'en soit la forme. La régulation de l'activation de la voie alterne du complément serait modifiée par le produit de ces gènes [1][2][3]. Plus récemment, il a été montré qu'un polymorphisme d'un nucléotide dans la région promotrice du gène HTRA1 (chromosome 10q26) conférerait un risque de 49,3 % de DMLA.…”

unclassified